Hill-Rom Holdings
Market Cap
US$7.1b
Last Updated
2021/03/01 23:27 UTC
Data Sources
Company Financials +
Executive Summary
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Solid track record and good value.
Similar Companies
Share Price & News
How has Hill-Rom Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HRC is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HRC's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
0.09%
HRC
0.2%
US Medical Equipment
-1.3%
US Market
1 Year Return
6.7%
HRC
33.4%
US Medical Equipment
41.9%
US Market
Return vs Industry: HRC underperformed the US Medical Equipment industry which returned 35.8% over the past year.
Return vs Market: HRC underperformed the US Market which returned 36.5% over the past year.
Shareholder returns
| HRC | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.09% | 0.2% | -1.3% |
| 30 Day | 11.7% | 1.9% | 7.5% |
| 90 Day | 11.5% | 8.4% | 15.9% |
| 1 Year | 7.7%6.7% | 34.5%33.4% | 44.8%41.9% |
| 3 Year | 32.4%29.0% | 77.2%72.8% | 49.1%41.0% |
| 5 Year | 136.7%125.4% | 156.9%138.4% | 113.1%92.8% |
Long-Term Price Volatility Vs. Market
How volatile is Hill-Rom Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Here's What We Learned About The CEO Pay At Hill-Rom Holdings, Inc. (NYSE:HRC)2 weeks ago | Simply Wall St
Is There An Opportunity With Hill-Rom Holdings, Inc.'s (NYSE:HRC) 24% Undervaluation?1 month ago | Simply Wall St
Should You Rely On Hill-Rom Holdings's (NYSE:HRC) Earnings Growth?Valuation
Is Hill-Rom Holdings undervalued compared to its fair value and its price relative to the market?
22.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HRC ($107.25) is trading below our estimate of fair value ($138.5)
Significantly Below Fair Value: HRC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HRC is good value based on its PE Ratio (29.5x) compared to the US Medical Equipment industry average (55.1x).
PE vs Market: HRC is poor value based on its PE Ratio (29.5x) compared to the US market (21.2x).
Price to Earnings Growth Ratio
PEG Ratio: HRC is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: HRC is good value based on its PB Ratio (4x) compared to the US Medical Equipment industry average (5.2x).
Next Steps
Future Growth
How is Hill-Rom Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
15.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRC's forecast earnings growth (15.7% per year) is above the savings rate (2%).
Earnings vs Market: HRC's earnings (15.7% per year) are forecast to grow slower than the US market (20% per year).
High Growth Earnings: HRC's earnings are forecast to grow, but not significantly.
Revenue vs Market: HRC's revenue (4% per year) is forecast to grow slower than the US market (10.4% per year).
High Growth Revenue: HRC's revenue (4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HRC's Return on Equity is forecast to be low in 3 years time (19.9%).
Next Steps
Past Performance
How has Hill-Rom Holdings performed over the past 5 years?
18.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HRC has high quality earnings.
Growing Profit Margin: HRC's current net profit margins (8.2%) are higher than last year (5.1%).
Past Earnings Growth Analysis
Earnings Trend: HRC's earnings have grown by 18.3% per year over the past 5 years.
Accelerating Growth: HRC's earnings growth over the past year (61.6%) exceeds its 5-year average (18.3% per year).
Earnings vs Industry: HRC earnings growth over the past year (61.6%) exceeded the Medical Equipment industry 9.8%.
Return on Equity
High ROE: HRC's Return on Equity (13.7%) is considered low.
Next Steps
Financial Health
How is Hill-Rom Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: HRC's short term assets ($1.3B) exceed its short term liabilities ($900.2M).
Long Term Liabilities: HRC's short term assets ($1.3B) do not cover its long term liabilities ($2.0B).
Debt to Equity History and Analysis
Debt Level: HRC's debt to equity ratio (103.8%) is considered high.
Reducing Debt: HRC's debt to equity ratio has reduced from 191.8% to 103.8% over the past 5 years.
Debt Coverage: HRC's debt is well covered by operating cash flow (27.6%).
Interest Coverage: HRC's interest payments on its debt are well covered by EBIT (5.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Hill-Rom Holdings's current dividend yield, its reliability and sustainability?
0.82%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HRC's dividend (0.82%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: HRC's dividend (0.82%) is low compared to the top 25% of dividend payers in the US market (3.76%).
Stability and Growth of Payments
Stable Dividend: HRC's dividends per share have been stable in the past 10 years.
Growing Dividend: HRC's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24.2%), HRC's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HRC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
John Groetelaars (53 yo)
2.75yrs
Tenure
US$7,628,308
Compensation
Mr. John P. Groetelaars serves as President, Chief Executive Officer and Director of Hill-Rom Holdings Inc. since May 14, 2018. Mr. Groetelaars served in a variety of progressive roles at C.R. Bard during ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD7.63M) is about average for companies of similar size in the US market ($USD6.35M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.75yrs | US$7.63m | 0.025% $ 1.8m | |
| Senior VP & CFO | 2.17yrs | US$2.69m | 0.0096% $ 677.4k | |
| Senior VP | 5.08yrs | US$2.05m | 0.048% $ 3.4m | |
| Senior VP & President of Front Line Care business | 2.17yrs | US$2.17m | 0.025% $ 1.8m | |
| Senior VP & President of Patient Support Systems | 4.25yrs | US$2.57m | 0.0094% $ 663.3k | |
| Senior Vice President of Operations | 3.42yrs | no data | no data | |
| VP, Controller & CAO | 2.75yrs | no data | 0.0049% $ 344.7k | |
| CTO & Senior VP | 10.17yrs | no data | no data | |
| Chief Information Officer & Senior VP | 5.08yrs | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | 0.018% $ 1.2m | |
| Chief Compliance Officer | 6.25yrs | no data | no data | |
| Vice President of Corporate Communications | no data | no data | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Management: HRC's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.75yrs | US$7.63m | 0.025% $ 1.8m | |
| Independent Director | 11.17yrs | US$283.19k | 0.0030% $ 213.1k | |
| Independent Director | 13.58yrs | US$287.19k | 0% $ 0 | |
| Independent Chairman of the Board | 2.92yrs | US$397.12k | 0.0081% $ 573.4k | |
| Independent Director | 3.92yrs | US$294.19k | 0% $ 0 | |
| Independent Director | 3.33yrs | US$299.19k | 0% $ 0 | |
| Independent Director | 1yr | US$244.97k | 0% $ 0 | |
| Independent Director | 7.92yrs | US$278.19k | 0% $ 0 | |
| Independent Director | 5.92yrs | US$275.19k | 0% $ 0 | |
| Independent Director | 3.92yrs | US$280.19k | 0.00045% $ 31.9k | |
| Independent Director | 1.75yrs | US$275.19k | 0% $ 0 |
3.9yrs
Average Tenure
62yo
Average Age
Experienced Board: HRC's board of directors are considered experienced (3.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Hill-Rom Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Hill-Rom Holdings, Inc.
- Ticker: HRC
- Exchange: NYSE
- Founded: 1915
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$7.079b
- Shares outstanding: 66.36m
- Website: https://www.hillrom.com
Number of Employees
Location
- Hill-Rom Holdings, Inc.
- 130 East Randolph Street
- Suite 1000
- Chicago
- Illinois
- 60601
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HRC | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jul 1971 |
| HB9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 1971 |
Biography
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgica...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/01 23:27 |
| End of Day Share Price | 2021/03/01 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.